Paul Murray

Prof. Paul Murray

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2007 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Gulisa TurashviliGulisa Turashvili
Gulisa Turashvili
JBJan Bouchal
Jan Bouchal
KBKarl Baumforth
Karl Baumforth
WWWenbin Wei
Wenbin Wei
MDMarta Dziechciarkova
Marta Dziechciarkova
ZKZdenek Kolar
Zdenek Kolar
Background: Invasive ductal and lobular carcinomas (IDC and ILC) are the most common histological types of breast cancer. Clinical follow-up data and metastatic patterns suggest that the development and progression of these tumors are different. The aim of our study was to identify gene expression profiles of IDC and ILC in relation to normal breast epithelial cells. Methods: We examined 30 samples (normal ductal and lobular cells from 10 patients, IDC cells from 5 patients, ILC cells from 5 patients) microdissected from cryosections of ten mastectomy specimens from postmenopausal patients. Fifty nanograms of total RNA were amplified and labeled by PCR and in vitro transcription. Samples were analysed upon Affymetrix U133 Plus 2.0 Arrays. The expression of seven differentially expressed genes (CDH1, EMP1, DDR1, DVL1, KRT5, KRT6, KRT17) was verified by immunohistochemistry on tissue microarrays. Expression of ASPN mRNA was validated by in situ hybridization on frozen sections, and CTHRC1, ASPN and COL3A1 were tested by PCR. Results: Using GCOS pairwise comparison algorithm and rank products we have identified 84 named genes common to ILC versus normal cell types, 74 named genes common to IDC versus normal cell types, 78 named genes differentially expressed between normal ductal and lobular cells, and 28 named genes between IDC and ILC. Genes distinguishing between IDC and ILC are involved in epithelial-mesenchymal transition, TGF-beta and Wnt signaling. These changes were present in both tumor types but appeared to be more prominent in ILC. Immunohistochemistry for several novel markers (EMP1, DVL1, DDR1) distinguished large sets of IDC from ILC. Conclusion: IDC and ILC can be differentiated both at the gene and protein levels. In this study we report two candidate genes, asporin (ASPN) and collagen triple helix repeat containing 1 (CTHRC1) which might be significant in breast carcinogenesis. Besides E-cadherin, the proteins validated on tissue microarrays (EMP1, DVL1, DDR1) may represent novel immunohistochemical markers helpful in distinguishing between IDC and ILC. Further studies with larger sets of patients are needed to verify the gene expression profiles of various histological types of breast cancer in order to determine molecular subclassifications, prognosis and the optimum treatment strategies.

11 December 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
MVMartina Vockerodt
Martina Vockerodt
LYLee Fah Yap
Lee Fah Yap
CSClaire Shannon‐Lowe
Claire Shannon‐Lowe
HCHelen Curley
Helen Curley
WWWenbin Wei
Wenbin Wei
Paul MurrayPaul Murray
Paul Murray

16 February 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
ADAmanda Dutton
Amanda Dutton
GRGary M Reynolds
Gary M Reynolds
CDChristopher W Dawson
Christopher W Dawson
LYLawrence S Young
Lawrence S Young
Paul MurrayPaul Murray
Paul Murray

1 October 2000 in Molecular Pathology
Verified
Journal Article
Open access
PDF file
KFK J Flavell
K J Flavell
Paul MurrayPaul Murray
Paul Murray
Hodgkin's disease is an unusual cancer because the malignant cells constitute only a minority of the total tumour mass and, as a consequence, the study of these cells has been a major challenge. Recently, the application of newer technologies, such as single cell polymerase chain reaction (PCR) and gene expression array analysis, to the study of Hodgkin's disease have yielded new insights into the pathogenesis of this tumour. In addition, the recognition that a proportion of Hodgkin's disease tumours harbour the Epstein-Barr virus (EBV) and that its genome is monoclonal in these tumours suggests that the virus contributes to the development of Hodgkin's disease in some cases. This review summarises current knowledge of the pathogenesis of Hodgkin's disease with particular emphasis on the association with EBV. J Clin Pathol: Mol Pathol

15 August 2019 in Blood
Verified
Journal Article
Closed access
PDF file
Paul MurrayPaul Murray
Paul Murray
Lawrence YoungLawrence Young
Lawrence Young
Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), this is not the case for classical Hodgkin lymphoma (cHL), a tumor with only a variable EBV association. In light of recent developments in immunotherapeutics and small molecules targeting EBV, we believe it is now timely to reevaluate the role of EBV in cHL pathogenesis.

27 November 2007 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
GKG Kapatai
G Kapatai
Paul MurrayPaul Murray
Paul Murray
Although the morphology of the pathognomonic Reed–Sternberg cells of Hodgkin lymphoma (HL) was described over a century ago, it was not until recently that their origin from B lymphocytes was recognised. The demonstration that a proportion of cases of HL harbour the Epstein–Barr virus (EBV) and that its genome is monoclonal in these tumours suggests that the virus contributes to the development of HL in some cases. This review summarises current knowledge of the pathogenesis of HL with particular emphasis on the association with EBV.